mhc class ii

Anti-Mouse MHC Class II (β chain) Antibody (KL277) is an IgG antibody inhibitor sourced from hamster or mouse and targets mouse MHC Class II.

Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is an IgG2a, κ inhibitory antibody derived from mice and targets mouse MHC class II proteins.

Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As, I-Ag7) Antibody (10-3.6.2) is an IgG2c, κ antibody inhibitor derived from mice, targeting murine MHC Class II molecules.

Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) is an IgG2a, κ antibody inhibitor derived from mice, designed to target MHC Class II in both mice and rats.

Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is an IgG2b antibody inhibitor derived from rats, specifically targeting mouse MHC Class II.

Anti-pan MHC Class II (HLA II) Antibody (IVA12) is an antibody targeting pan MHC Class II and can be used for life science research.

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is an IgG2a, κ antibody inhibitor derived from mice that targets monkey or human MHC class II.

MHC class II antigen (45-57) [Homo sapiens] is a peptide with the sequence H2N-Asp-Leu-Asp-Lys-Lys-Glu-Thr-Val-Trp-His-Leu-Glu- Glu-OH, MW= 1868.07. MHC (major histocompatibility complex) class II molecules are found only on antigen-presenting cells and l

Corticosterone (Kendall's compound B) is an adrenocortical steroid with salocorticoid and glucocorticoid activity that is orally active. Corticosterone is involved in the regulation of energy, immune responses, and stress responses in the body.

D-α-Methyl DOPA is an inhibitor of DQ8 peptide binding to MHC class II molecules. By occupying a binding site in the DQ8 peptide groove, D-α-Methyl DOPA prevents the DQ8 peptide from associating with MHCII molecules. This action blocks presentation to CD4+ T cells, thereby slowing or hindering the onset or progression of type 1 diabetes or celiac disease.

Concanamycin B is a macrolide antibiotic that selectively inhibits vacuolar type H+-ATPases (IC50 = 5 nM), thereby blocking vacuolar organelle acidification and early to late endosomal transport. It interferes with bone resorption, maturation of CD8 T lymphocytes, and prevents processing of major histocompatibility complex (MHC) class II precursors in human B cells, inhibiting MHC class II molecule expression on the cell surface.

Cyclic di-IMP (sodium salt) (c-di-IMP) is a synthetic second messenger structurally related to the bacterial second messengers cyclic di-GMP and cyclic di-AMP . C-di-IMP has adjuvant properties when co-administered with antigens in vitro and by mucosal routes in vivo. C-di-IMP enriches the population of MHC class I and II, CD80, CD86, CD40, and CD54 positive dendritic cells derived from murine bone marrow. It also stimulates macrophages at 500 ng/ml. Mice immunized with β-galactosidase (β-gal) plus c-di-IMP through the intranasal route show a humoral immune response, evidenced by an increase in IgG titers up to 2-fold compared to mice immunized with β-gal alone. Mice immunized with β-gal plus c-di-IMP also exhibit a Th1/Th2 response, indicating that the adjuvant activity of c-di-IMP leads to a cellular immune response as well.

GAD65 (206-220) is a synthetic peptide derived from glutamic acid decarboxylase (GAD) 65, specifically corresponding to residues 180-188. It is known that GAD65 interacts with I-Ag7 MHC class II molecules and is a significant pancreatic antigen that self-reactive T cells target in type I diabetes mellitus.

NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide interacting with various HLA-DR and HLA-DP4 molecules, inducing activation of CD4+ T cells with Th1-type and Th-2/Th0-type responses when presented with these molecules.

FGF22-IN-1 is a potential CD4 N-terminal immunoglobulin variable region-like domain (CD4 D1) inhibitor.FGF22-IN-1 inhibits the interaction between CD4 and major histocompatibility complex (MHC) class II proteins and suppresses the immune response.

OVA Peptide (323-339) is an immunodominant epitope peptide derived from chicken ovalbumin (OVA), which is the major MHC class II-restricted T-cell epitope that specifically binds H2-IAd molecules, and a B-cell epitope that is recognized by IgE antibodies. It is commonly used in the study of egg allergy, and is able to induce strong Th2-type immune responses and IgE antibody production in mice.

Eftilagimod alfa (IMP321), a recombinant LAG-3Ig fusion protein, binds to MHC class II and mediates the activation of antigen-presenting cells (APCs), which in turn activates CD8 T-cells. It is utilized in the research of metastatic melanoma and metastatic breast carcinoma [1].

Influenza NP (311-325) is a biologically active peptide consisting of amino acids 311 to 325 from the influenza virus nucleoprotein (NP). As a bona fide MHC class II-restricted epitope, it is critical for studying host immune responses during viral infection, inducing robust gamma interferon (IFN-gamma) production in intracellular cytokine assays without stimulating CD8 T-cells in mice. The presence of Glutamine (Q) or Glutamic acid (E) at the N-terminus can lead to spontaneous formation of Pyroglutamyl (pGlu) peptides, enhancing peptide stability against gastrointestinal proteases. These peptides are considered a normal variant and included in peptide purity measurements in HPLC analysis.

Favezelimab (MK-4280), a humanized monoclonal antibody directed against LAG-3, inhibits the molecular interaction between LAG-3 and its ligand MHC class II, thereby restoring T-cell function. Favezelimab (MK-4280) has been evaluated as a candidate for colorectal cancer (CRC) research, particularly in studies that investigate synergistic effects in combination with the PD-L1 inhibitor Pembrolizumab .

Encelimab, an anti-LAG3 monoclonal antibody, prevents the interaction between LAG-3 and MHC class II molecules, thereby facilitating the activation of T-cells and promoting an enhanced anti-tumor immune response. Encelimab demonstrates efficacy in preclinical models, as it has been observed to reduce tumor burden when administered either as a monotherapy or in conjunction with an anti-PD-1 antibody in lymphoma mouse models, specifically the A20 cell xenograft model.

CFP10 (71–85) is an immunologically active peptide that induces IFN-γ production and cytotoxic T lymphocyte (CTL) activity in CD4+ and CD8+ T cells from individuals with diverse MHC class II and I expression profiles.

M04 acts as a stimulator of interferon genes (STING) agonist, effectively inducing IFN reporter gene expression in HEK293T cells equipped with wild-type human STING. Its activity is specific, not affecting HEK293T cells with the R71H-G230A-R293Q (HAQ) human STING variant or mouse RAW 264.7 cells, showcasing allelic- and species-dependent effects at a concentration of 75 µM. This compound also stimulates the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At 50 µM, M04 enhances human monocyte-derived dendritic cells' expression of HLA-DR (MHC class II receptor) and co-stimulatory molecules CD40, CD80, and CD86, improving T cell cross-priming in an ex vivo assay.

Zharp1-211 is a selective and potent RIPK3 inhibitor that significantly reduces the expression of JAK/ stat1-mediated chemokines and MHC class II molecules in IECs, restores intestinal homeostasis, and inhibits graft-versus-host disease (GVHD) for gastrointestinal inflammation.

Pristane-D40 is the deuterated form of Pristane (TN6925) (Norphytane), a naturally occurring hydrocarbon oil found in trace amounts in various plants and marine organisms, and considered one of the most active components in mineral oil. As a non-antigenic adjuvant, Pristane (TN6925) can induce MHC class II-restricted arthritis T cells in rats.